secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2026-03-19T23:59:59+00:00
Accession:  0001104659-26-031309
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics FY2025 net loss $12.2M; cash $17M; APOLLO 66% ORR in NHL
----------------------------------------------------------------------------

- Net loss of $12.2M vs $10.7M in 2024; R&D spend $11.8M (down from $13.5M).
- Cash $17M at Dec 31, 2025; expected to fund ops through Q4 2026 without new grants.
- Phase 1 APOLLO data: 66% objective response rate in relapsed NHL, 50% complete responses.
- MT-601 pancreatic cancer program to initiate in Q2 2026; Nature Medicine publication Jan 2026.
- New board member Kathryn Penkus Corzo appointed Nov 2025; Cellipont manufacturing collaboration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465926031309/0001104659-26-031309-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465926031309/tm268941d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-031309

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer